Shun Shimizu
A5013328355- CAR-T cell therapy research
- Lung Cancer Research Studies
- Cancer therapeutics and mechanisms
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- RNA and protein synthesis mechanisms
- RNA Interference and Gene Delivery
- Tree Root and Stability Studies
- Geotechnical Engineering and Underground Structures
- Advanced biosensing and bioanalysis techniques
- CRISPR and Genetic Engineering
- Nanoplatforms for cancer theranostics
- Concrete Corrosion and Durability
- Advanced Fiber Optic Sensors
- Adenosine and Purinergic Signaling
- Cell Adhesion Molecules Research
- Structural Load-Bearing Analysis
- Wood Treatment and Properties
Tokyo Institute of Technology
2008-2022
Abstract Small-cell lung cancer (SCLC) is an aggressive for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives ICI-resistant tumors, but not all patients with SCLC responsive. Herein, to integrate CD137 costimulatory function into a engager format and thereby augment efficacy, we generated CD3/CD137 dual-specific Fab engineered DLL3-targeted trispecific antibody (DLL3 trispecific). The was competitively...
The extracellular adenosine triphosphate (ATP) concentration is highly elevated in the tumor microenvironment (TME) and remains tightly regulated normal tissues. Using phage display technology, we establish a method to identify an antibody that can bind antigen only presence of ATP. Crystallography analysis reveals ATP bound between antibody-antigen interface serves as switch for binding. In transgenic mouse model overexpressing systemically, binds tumors with minimal binding tissues plasma...
In the New Austrian Tunneling Method (NATM) of tunnel design and construction, it is important to know actual compressive strength lining concrete at early ages, which determines time demolding its future durability. The degree hydration reaction in-place regarded as a useful reference estimate development concrete. Based on concept On-Site Visualization, this paper presents new approach monitoring hardening progress fresh concrete/mortar using plastic optical fiber (POF) sensors. principle...
Abstract Background: Despite the approval of immune checkpoint inhibitors (ICIs), prognosis small cell lung cancer (SCLC) remains poor. DLL3 is upregulated in SCLC whereas expression normal tissues minimal, representing favorable profile as a therapeutic target. T engager (TCE) potent immunotherapy that redirects cells to tumors expressing specific antigen. Unlike ICIs, TCEs do not require recognition tumor antigens by and thus could be an alternative approach target where benefit ICIs...
<p>Supplementary Figure S2. Overview of the generation CD3/CD137 dual-specific Fab</p>
<div>Abstract<p>Small-cell lung cancer (SCLC) is an aggressive for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives ICI-resistant tumors, but not all patients with SCLC responsive. Herein, to integrate CD137 costimulatory function into a engager format and thereby augment efficacy, we generated CD3/CD137 dual-specific Fab engineered DLL3-targeted trispecific antibody (DLL3 trispecific). The...
<p>Supplementary Figure S4. DLL3 trispecific induces multiple cytokine production and DLL3- dependent cytotoxicity</p>
<p>Supplementary Figure S6. Cross-reactivity of DLL3 trispecific.</p>
<p>Supplementary Figure S9. The use of dexamethasone and tocilizumab does not limit the antitumor efficacy DLL3 trispecific.</p>
<p>Supplementary Figure S1. The composition of the antibodies</p>
<p>Supplementary Figure S8. DLL3 trispecific induced activation of tumor-infiltrating T cells.</p>
<p>Supplementary Figure S3. Binding of DLL3 trispecific to FcγRs, C1q, and FcRn. (</p>
<p>Supplementary Figure S7. DLL3 expression of SCLC xenograft models.</p>
<p>pharmacokinetic parameters of DLL3 trispecific in cynomolgus monkeys</p>
<p>Supplementary Figure S4. DLL3 trispecific induces multiple cytokine production and DLL3- dependent cytotoxicity</p>
<p>Supplementary Figure S8. DLL3 trispecific induced activation of tumor-infiltrating T cells.</p>
<p>Supplementary Figure S2. Overview of the generation CD3/CD137 dual-specific Fab</p>
<p>Supplementary Figure S6. Cross-reactivity of DLL3 trispecific.</p>
<p>Supplementary Methods</p>
<p>pharmacokinetic parameters of DLL3 trispecific in cynomolgus monkeys</p>
<p>Supplementary Figure S7. DLL3 expression of SCLC xenograft models.</p>
<p>Supplementary Figure S5. DLL3 trispecific induces cytotoxicity against non-SCLC tumors.</p>
<p>Supplementary Methods</p>